Business
Director Appointment
Director Appointment.
About this update from Skinbiotherapeutics Plc
[{"type":"text","content":"\n \nRNS Number : 5481W SkinBioTherapeutics PLC 18 April 2019 \n\nSkinBioTherapeutics plc\n(\"SkinBioTherapeutics\" or the \"Company\")\n \nDirector Appointment\n \nManchester, UK - 18 April 2019 - SkinBioTherapeutics plc (AIM: SBTX or the \"Company\"), a life sciences company focused on skin health, announces the appointment of Stuart John Ashman to the Board as an Executive Director with effect from 18 April 2019. As previously stated in the Company's announcement dated 29 March 2019, the intention is for Mr Ashman to succeed Dr Cath O'Neill as Chief Executive Officer following a period of transition, which will enable him to gain an understanding of the business and allow for an orderly handover. This will also enable Dr O'Neill to focus on the scientific development of the Company and the ongoing commercial discussions she has initiated.\n \nPrior to joining the Company, Mr Ashman served as CEO of Onbone Oy (\"Onbone\"), a Finnish private equity-backed medical device company. In this role, he successfully established a global sales force and distribution network and led the growth of a multi-million pound business.\n \nPrior to Onbone, Mr Ashman was President/CEO of Andover Healthcare Inc., a US-based wound management manufacturer, and before then, was President/CEO of TI Group, a UK-based medical/engineering company. Stuart also served as Senior VP, Global Sales & Strategic Marketing, BSN Medical (Biersdorf, Smith and Nephew) and was Director of Sales & Marketing at Smith & Nephew Plc, in its Woundcare, Casting & Bandaging division.\n \nMartin Hunt, Non-Executive Chairman of SkinBioTherapeutics, commented:\n\"Stuart's appointment as a director adds further commercial capability to the board. He has a considerable network within the medtech and life science industries and he has the experience and drive to take us forward on the next stage of the Company's development\".\n \n \nOther than as set out below, there are no other matters required to be disclosed under Schedule 2 paragraph (g) of the AIM Rules in relation to the appointment of Stuart John Ashman, aged 52.\n \n\n\n\nCurrent Directorships\n\n\nFormer Directorships within the last five years\n\n\n\n\nAfterall Ltd\nHero Healthcare Limited\n \n\n\nAshman Industries Ltd1\nLupton-Smallshaw Limited2\nOnbon...